Related Experiment Videos
Limited sampling models for HA-1A IgM monoclonal antibody
J M Hardin1, M B Khazaeli, I E Allen
1Comprehensive Cancer Center, University of Alabama, Birmingham 35294.
Human Antibodies and Hybridomas
|January 1, 1990
Summary
Limited sampling models were developed to predict the area under the concentration-time curve (AUC) for HA-1A, a human IgM monoclonal antibody. These models accurately estimate AUC from sparse data, aiding future clinical trials.
Area of Science:
- Pharmacokinetics
- Monoclonal Antibody Therapy
- Biologics Development
Background:
- HA-1A is a human IgM monoclonal antibody.
- Accurate pharmacokinetic profiling is crucial for therapeutic efficacy and safety.
- Limited sampling strategies can optimize clinical trial efficiency.
Purpose of the Study:
- To develop and validate limited sampling models for predicting the area under the concentration-time curve (AUC) of HA-1A.
- To assess the predictive performance of these models using sparse serum concentration data.
- To facilitate the correlation of estimated AUC with clinical outcomes in larger studies.
Main Methods:
- Development of limited sampling models using regression analysis on pharmacokinetic data from 28 patients.
- Patients received HA-1A infusions at 25 mg, 100 mg, and 250 mg doses.
- Validation of models using coefficients of determination and predictive error metrics.
Main Results:
- Four validated limited sampling models were identified.
- Models demonstrated high predictive accuracy for AUC, with R-squared values from 0.92 to 0.97.
- Low relative root mean squared predictive error (7.1-10.8%) and relative mean predictive error (-4.5 to +6.9%) were achieved.
Conclusions:
- The developed limited sampling models are effective for predicting HA-1A AUC from sparse data.
- These models can significantly aid in the analysis of larger Phase II/III clinical studies.
- Estimated AUC can be correlated with demographic data, toxicity, and efficacy, optimizing HA-1A therapeutic strategies.